Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 38.11 USD -1.73% Market Closed
Market Cap: 1.9B USD

Immunocore Holdings PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Immunocore Holdings PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Income
-ÂŁ70.5m
CAGR 3-Years
18%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Income
-$201.1m
CAGR 3-Years
-9%
CAGR 5-Years
-109%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Operating Income
-$285.7m
CAGR 3-Years
-41%
CAGR 5-Years
-48%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Income
ÂŁ68.6m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
6%
Avacta Group PLC
LSE:AVCT
Operating Income
-ÂŁ29.6m
CAGR 3-Years
-3%
CAGR 5-Years
-15%
CAGR 10-Years
-25%
Oxford BioMedica PLC
LSE:OXB
Operating Income
-ÂŁ30.7m
CAGR 3-Years
-20%
CAGR 5-Years
-19%
CAGR 10-Years
-9%
No Stocks Found

Immunocore Holdings PLC
Glance View

Market Cap
1.9B USD
Industry
Biotechnology

Immunocore Holdings PLC stands as a pioneering force in the field of immunotherapy, leveraging its proprietary T-cell receptor (TCR) technology to transform the treatment landscape for various severe diseases. Rooted in cutting-edge science, the British biotech firm develops novel therapeutic agents targeting cancer, infectious diseases, and autoimmune conditions. Its leading platform technology, known as ImmTACs (Immune Mobilizing Monoclonal TCRs Against Cancer), ingeniously redirects T-cells—an integral component of the immune system—to recognize and obliterate cancerous cells in a highly targeted manner. By focusing on ultra-specific peptide-major histocompatibility complex (pMHC) targets, Immunocore meticulously designs its therapies to minimize off-target effects and maximize efficacy in tackling conditions that have eluded traditional treatment methods. Financially, Immunocore operates through a strategic blend of commercial and collaborative partnerships, alongside its independent pipeline advancements. It generates revenue by licensing its innovative technology to larger pharmaceutical entities that seek to add cutting-edge biologics to their portfolios. Additionally, milestone and royalty payments from collaborative research initiatives contribute significantly to its financial foundation. These partnerships not only bolster Immunocore's revenue streams but also accelerate its research and development efforts, enabling a faster path to market for its groundbreaking treatments. As a result, the company stands at the confluence of science and commerce, channeling its unique TCR technology to make meaningful strides in medical innovation and patient care.

IMCR Intrinsic Value
64.96 USD
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Immunocore Holdings PLC's Operating Income?
Operating Income
-70.5m GBP

Based on the financial report for Dec 31, 2024, Immunocore Holdings PLC's Operating Income amounts to -70.5m GBP.

What is Immunocore Holdings PLC's Operating Income growth rate?
Operating Income CAGR 5Y
10%

Over the last year, the Operating Income growth was -18%. The average annual Operating Income growth rates for Immunocore Holdings PLC have been 18% over the past three years , 10% over the past five years .

Back to Top